Valeritas Holdings, New Study Results Pump Up V-Go Insulin Delivery Device

NEW YORK, NY / ACCESSWIRE / June 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (NASDAQ: VLRX) is a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy.

The company shares jumped this week after the company advised positive results from its ENABLE study, showing that patients who switched from insulin pens and syringes to the company’s wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose.

In Monday’s session VLRX shares, in intra-day trading, moved from $1.63/share to $2.08 per share on unusually high trading volume of 26 million shares.

Results from the ENABLE study and the potential V-Go market numbers READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/valeritas-holdings/

The VLRX primary target market consists of the approximately 5.6 million patients with type 2 diabetes who currently take injectable insulin, of which up to 4.5 million may not be achieving their target blood glucose goal. This patient population represents a $16.5 billion annual U.S. market when applying the annual wholesale acquisition cost, or WAC, of V-Go to the 4.5 million patients not achieving glycemic control.

Get the Q1 financial data and read all about the V-Go product here READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/valeritas-holdings/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 503669